Skip to main content
BWAY
NASDAQ Industrial Applications And Services

BrainsWay Reports Record Q4 & Full Year 2025 Financial Results, Projects Strong 27-30% Revenue Growth in 2026

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$13.85
Mkt Cap
$490.365M
52W Low
$3.92
52W High
$13.87
52W Position info
253% above low
Off High info
at 52W high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

BWAY has more than doubled off its 52-week low of $3.92.

Summary

BrainsWay reported record Q4 and full year 2025 financial results with substantial revenue and net income growth, alongside strong 2026 guidance and key operational milestones.


Key Events · Earnings and Guidance · BWAY

  • Record Q4 and Full Year 2025 Financial Performance

    Reported Q4 2025 revenue growth of 27% to $14.5 million and full year 2025 revenue growth of 27% to $52.2 million. Net income for the full year increased by 161% to $7.6 million.

  • Strong 2026 Financial Guidance Issued

    Projected full year 2026 revenue of $66 million to $68 million, representing 27% to 30% growth, and anticipated Adjusted EBITDA of $12 million to $14 million, an 86% to 100% increase.

  • Significant Operational Growth and Regulatory Milestones

    Increased remaining performance obligations by 43% to approximately $70 million and shipped 95 Deep TMS™ systems in Q4 2025, growing the total installed base to around 1,700 systems. The FDA also granted label expansion for Deep TMS for adolescents with MDD and the company secured its first insurer coverage for the accelerated SWIFT™ protocol.


Analysis · BWAY · Industrial Applications And Services

BrainsWay has delivered a robust earnings report, showcasing significant year-over-year growth in both revenue and profitability for Q4 and the full year 2025. The company's positive 2026 guidance, projecting continued strong revenue and Adjusted EBITDA growth, indicates sustained operational momentum. Key drivers include FDA label expansion for Deep TMS in adolescents and securing the first insurer coverage for its accelerated SWIFT™ protocol, which are expected to fuel further market penetration and revenue generation. This strong performance and optimistic outlook could reinforce investor confidence, especially as the stock trades near its 52-week high.

At the time of this filing, BWAY was trading at $13.85 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $490.4M. The 52-week trading range was $3.92 to $13.87. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BWAY - Latest Insights

BWAY
Jun 29, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $14.48
Real-time Price: $15.27 info
Change: +$0.790 (+5%) info
Market Cap: $620.027M info
BWAY
Jun 22, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $14.81
Real-time Price: $15.27 info
Change: +$0.460 (+3%) info
Market Cap: $620.027M info
BWAY
Jun 09, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $14.90
Real-time Price: $15.27 info
Change: +$0.370 (+2%) info
Market Cap: $620.027M info
BWAY
May 18, 2026, 7:37 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $15.00
Real-time Price: $15.27 info
Change: +$0.270 (+2%) info
Market Cap: $620.027M info
BWAY
May 13, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $16.31
Real-time Price: $15.27 info
Change: -$1.04 (-6%) info
Market Cap: $620.027M info